
HUTCHMED begins Phase III trial of PDAC treatment
Biopharmaceutical company HUTCHMED has launched the Phase III trial evaluating the combination of surufatinib, camrelizumab, nab-paclitaxel and gemcitabine as a treatment for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). PDAC is a highly aggressive form of cancer, representing over 90% of pancreatic cancer cases. Globally, an estimated 511,000 people were diagnosed… Read More














